BREAKOUT! First RSV vaccine approved for the elderly
Within Anima Research, various clinical trials are being conducted in the fight against RSV. Here, the quality of data collection and ensuring patient safety are central. All these efforts, of which we have been a part, have led to an important breakthrough: the approval of a first vaccine for protection against infection with the RS Virus (RSV vaccine)!
RSV is a common, infectious virus that can lead to potentially serious respiratory diseases. The approval is based on data from the positive AReSVi-006 phase III trial in which Anima Research enrolled 228 subjects This study demonstrates exceptional efficacy in older adults, including those with underlying medical conditions and those with severe RSV disease.
The various studies are still ongoing, but we are already happy to share these results with you
: https://www.gsk.com/en-gb/media/press-releases/us-fda-approves-gsk-s-arexvy-the-world-s-first-respiratory-syncytial-virus-rsv-vaccine-for-older-adults/
Would you like to be part of clinical trials yourself? Then register now below or check out
all our current studies on the website! https://www.animaresearch.com/studies/